NasdaqGS:AMGNBiotechs
Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?
Amgen recently received a positive opinion from the European Medicines Agency’s CHMP to expand Repatha’s use to adults with or at high risk for atherosclerotic cardiovascular disease in Europe, following Phase 3 VESALIUS-CV data showing meaningful reductions in first major cardiovascular events and LDL-C levels.
This expanded cardiovascular prevention use, if approved by the European Commission, could broaden Repatha’s eligible patient pool and reinforce Amgen’s position in treating...